European Journal of Dermatology

, Volume 25, Issue 5, pp 410–417 | Cite as

Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain

  • Lluís Puig
  • Francisco Camacho
  • Vicente García-Patos
  • Maria Luisa Fernández-Díaz
  • Amparo Marquina
  • Carmen García-Calvo



Information on the long-term efficacy of etanercept (ETN) treatment of moderate-to-severe psoriasis according to the Summary of Product Characteristics (SmPC) is scarce.


We report the efficacy results of an observational clinical trial including 202 patients treated for 12 months with ETN according to SmPC.


Concomitant topical treatment was permitted throughout the study period. Efficacy assessment was done by intention-to-treat analysis with last observation carried forward.


Mean%Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) decreased from 39.0% and 22.2% at baseline to 7.9% and 4.4%, respectively, at 12 months. Throughout the study duration, PASI 50, PASI 75 and PASI 90 response rates ranged from 72.8% to 95.7%, 55.6% to 84.3%, and 36.1% to 62.2%, respectively. Body mass index and body weight had minor effects on treatment efficacy.


ETN treatment according to the SmPC provided sustained improvement of psoriasis throughout one year.

Key words

efficacy etanercept psoriasis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferrándiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001; 15: 20–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70: 871–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Ferrándiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr 2014; 105: 504–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1–10.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013; 104: 694–709.PubMedCrossRefGoogle Scholar
  8. 8.
    Pfizer Limited. Summary of Product Characteristics. Enbrel 25 mg powder and solvent for solution for injection. Available at: (accessed 15 Jul 2014).Google Scholar
  9. 9.
    Puig L, Camacho Martinez FM, Gimeno Carpio E, López-Ávila A, Garcia-Calvo C. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology 2012; 225: 220–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Williams JR. The Declaration of Helsinki and public health. Bull World Health Organ 2008; 86: 650–2.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Griffiths CE, Strober BE, van de Kerkhof P, et al, & ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis. N Engl J Med 2010; 362: 118–28.PubMedCrossRefGoogle Scholar
  12. 12.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 2009; 10: 319–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177–85.PubMedGoogle Scholar
  14. 14.
    National Institute for Health and Clinical Excellence. The assessment and management of psoriasis. Available at: (accessed 25 Jul 2014).Google Scholar
  15. 15.
    Arcese A, Aste N, Bettacchi A, et al. Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation. Clin Drug Investig 2010; 30: 507. 16.PubMedCrossRefGoogle Scholar
  16. 16.
    Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-tosevere psoriasis (the PRISTINE trial). J Dermatolog Treat 2013; 24: 169–78.PubMedCrossRefGoogle Scholar
  17. 17.
    Carrascosa JM, Rocamora V, Fernández-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr 2014; 105: 31–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006; 54: S101–11.PubMedCrossRefGoogle Scholar
  20. 20.
    Esposito M, Mazzotta A, Saraceno R, Schipani C, Chimenti S. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22: 219–25.PubMedGoogle Scholar
  21. 21.
    De Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther 2014; 14: 749–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Segaert S. Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update. J Inflamm Res 2009; 2: 29–36.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res 2013; 22: 2489–99.PubMedCrossRefGoogle Scholar
  25. 25.
    Fernández-Torres RM, Paradela S, Fonseca E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatolog Treat 2014; 25: 54–6.PubMedCrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2015

Authors and Affiliations

  • Lluís Puig
    • 1
  • Francisco Camacho
    • 2
  • Vicente García-Patos
    • 3
  • Maria Luisa Fernández-Díaz
    • 4
  • Amparo Marquina
    • 5
  • Carmen García-Calvo
    • 6
  1. 1.Dermatology DepartmentHospital de la Santa Creu i Sant PauBarcelona, CatalunyaSpain
  2. 2.Departamento de DermatologíaHospital Virgen de la MacarenaSevillaSpain
  3. 3.Hospital Universitario Vall d’HebronBarcelonaSpain
  4. 4.Servicio de DermatologíaHospital Universitario Lucus AugustiLugoSpain
  5. 5.Servicio de DermatologíaHospital Universitario Doctor PesetValenciaSpain
  6. 6.Departamento Médico PfizerMadridSpain

Personalised recommendations